Formosa Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 10, 2021
Share
Formosa Laboratories, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was TWD 689.67 million compared to TWD 814.72 million a year ago. Net loss was TWD 384.56 million compared to net income of TWD 100.89 million a year ago. Basic loss per share from continuing operations was TWD 3.2 compared to basic earnings per share from continuing operations of TWD 0.93 a year ago. Diluted loss per share from continuing operations was TWD 3.2 compared to diluted earnings per share from continuing operations of TWD 0.85 a year ago.
For the nine months, sales was TWD 2,253.3 million compared to TWD 2,265.07 million a year ago. Net income was TWD 1,425.88 million compared to TWD 533.19 million a year ago. Basic earnings per share from continuing operations was TWD 12.69 compared to TWD 5.09 a year ago. Diluted earnings per share from continuing operations was TWD 11.76 compared to TWD 4.6 a year ago.
Formosa Laboratories, Inc. is a Taiwan-based company principally engaged in the development, production and distribution of ultraviolet (UV)-proof active ingredients, bulk pharmaceutical chemicals, antibody drug conjugates, as well as the provision of customized services. The Company primarily provides UV-proof active ingredients series products, vitamin D derivative series products, anti-inflammatory analgesic series products, steroid, anti-cancer drugs, cholesterol phosphate binding agents, nuclear magnetic resonance (NMR) reagents, respiratory disease drugs, central nervous system drugs, immune system regulators and weight loss drugs, as well as customized research and development and original equipment manufacturing (OEM) services. The Company distributes its products to Europe, the Americas, Asia and other markets.
FORMOSA LABORATORIES, INC. 
